| Literature DB >> 35291530 |
Muhammer Ergenç1, Tevfik Kıvılcım Uprak2.
Abstract
INTRODUCTION: Esophagogastroduodenoscopy is frequently used for the elderly population. Older patients are more fragile than younger patients because of multiple age-related chronic diseases and the common use of polypharmacy. There is no adequate data in the existing literature regarding the application of upper gastrointestinal system endoscopy in the elderly population. Therefore, in this article, we evaluated esophagogastroduodenoscopy procedures that were performed on patients aged 75 years or older in the secondary care hospital.Entities:
Keywords: aged; digestive system; esophagogastroduodenoscopy; gastrointestinal endoscopy; gastroscopy; octogenarians
Year: 2022 PMID: 35291530 PMCID: PMC8896878 DOI: 10.7759/cureus.21846
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Flowchart of patient selection
GI: gastrointestinal
Patients’ demographics, indications, and endoscopic and pathological findings
GI: gastrointestinal; VRF: very relevant findings (esophageal malignancy, gastric ulcer, gastric malignancy, and duodenal ulcer)
| Parameters | Total n: 202 (%) | Age group 75-79, n | Age group ≥80, n | P-value |
| Age (years, mean-range) | 79 | |||
| Sex | 0.98 | |||
| Female | 131 | 81 | 50 | |
| Male | 71 | 44 | 27 | |
| Endoscopy indications | 0.48 | |||
| Dyspepsia | 52 (25.7%) | 34 | 18 | |
| Abnormal imaging | 10 (5.0%) | 8 | 2 | |
| Reflux | 21 (10.4%) | 12 | 9 | |
| Dysphagia | 11 (5.4%) | 5 | 6 | |
| Upper GI bleeding | 25 (12.4%) | 13 | 12 | |
| Anemia | 21 (10.4%) | 11 | 10 | |
| Vomiting | 10 (5.0%) | 6 | 4 | |
| Screening/surveillance | 21 (10.4%) | 13 | 8 | |
| Weight loss | 13 (6.4%) | 8 | 5 | |
| Abdominal pain | 18 (8.9%) | 15 | 3 | |
| Endoscopic diagnosis | 0.07 | |||
| Esophagitis | 15 (7.4%) | 11 | 4 | |
| Bile reflux gastritis | 4 (2.0%) | 1 | 3 | |
| Duodenal ulcer | 4 (2.0%) | 2 | 2 | |
| Duodenal polyp | 2 (1.0%) | 0 | 2 | |
| Normal finding | 19 (9.4%) | 16 | 3 | |
| Gastric ulcer | 13 (6.4%) | 7 | 6 | |
| Duodenitis | 9 (4.5%) | 6 | 3 | |
| Gastric polyp | 10 (5.0%) | 7 | 3 | |
| Other | 5 (2.5%) | 4 | 1 | |
| Esophageal malignancy | 4 (2.0%) | 1 | 3 | |
| Esophageal varices | 3 (1.5%) | 1 | 2 | |
| Hiatal hernia | 15 (7.4%) | 8 | 7 | |
| Antral gastritis | 27 (13.4%) | 21 | 6 | |
| Pangastritis | 24 (11.9%) | 17 | 7 | |
| Gastric erosion | 16 (7.9%) | 9 | 7 | |
| Gastric malignancy | 18 (8.9%) | 7 | 11 | |
| Findings secondary to operation | 14 (6.9%) | 7 | 7 | |
| Very Relevant Findings (VRF) | 39 (19.3%) | 17 (13.6%) | 22 (28%) | 0.008 |
| Pathological Finding | 0.24 | |||
| Chronic active gastritis | 86 (42.6%) | 54 | 32 | |
| Low-grade dysplasia | 3 (1.5%) | 2 | 1 | |
| Mucinous carcinoma | 2 (1.0%) | 0 | 2 | |
| Inflammatory fibroid polyp | 1 (0.5%) | 0 | 1 | |
| Chronic gastritis | 65 (32.2%) | 45 | 20 | |
| Adenocarcinoma | 17 (8.4%) | 7 | 10 | |
| Hyperplastic polyp | 6 (3.0%) | 4 | 2 | |
| Ulceration | 4 (2.0%) | 2 | 2 | |
| Duodenitis | 1 (0.5%) | 1 | 0 | |
| Chronic esophagitis | 2 (1.0%) | 0 | 2 | |
| Erosive gastritis | 3 (1.5%) | 2 | 1 | |
Comparison of pathologic outcomes by age groups
| Parameters | Total n: 202 (%) | Age group 75-79, n | Age group ≥80, n | P-value |
| Atrophy | 0.9 | |||
| None | 147 (91%) | 98 | 49 | |
| Mild | 10 (6%) | 7 | 3 | |
| Moderate | 5 (3%) | 3 | 2 | |
| Helicobacter pylori | 0.45 | |||
| None | 36 (22.4%) | 27 | 9 | |
| Mild | 93 (57.8%) | 60 | 33 | |
| Moderate | 32 (19.9%) | 20 | 12 | |
| Intestinal metaplasia | 0.58 | |||
| None | 127 (78.4%) | 88 | 39 | |
| Mild | 18 (11%) | 10 | 8 | |
| Moderate | 15 (9.3%) | 9 | 6 | |
| Severe | 2 (1.2%) | 1 | 1 | |
| Chronic inflammation | 0.191 | |||
| Mild | 110 (68%) | 77 | 33 | |
| Moderate | 52 (32%) | 31 | 21 | |
| Activity | 0.38 | |||
| None | 75 (46.3%) | 52 | 23 | |
| Mild | 70 (43.2%) | 47 | 23 | |
| Moderate | 16 (9.9%) | 9 | 7 | |
| Severe | 1 (0.6%) | 0 | 1 | |
Correlations between pathologic outcomes
*Correlation is significant at the 0.05 level (Two-tailed) **Correlation is significant at the 0.01 level (Two-tailed)
| Atrophy | Helicobacter pylori | Intestinal metaplasia | Chronic inflammation | Activity | |
| Atrophy | 1.000 | −0.157* | 0.616** | 0.054 | 0.151 |
| . | 0.046 | 0.000 | 0.495 | 0.055 | |
| Helicobacter pylori | −0.157* | 1.000 | −0.061 | 0.453** | 0.431** |
| 0.046 | . | 0.439 | 0.000 | 0.000 | |
| Intestinal metaplasia | 0.616** | −0.061 | 1.000 | 0.220** | 0.132 |
| 0.000 | 0.439 | . | 0.005 | 0.094 | |
| Chronic inflammation | 0.054 | 0.453** | 0.220** | 1.000 | 0.498** |
| 0.495 | 0.000 | 0.005 | . | 0.000 | |
| Activity | 0.151 | 0.431** | 0.132 | 0.498** | 1.000 |
| 0.055 | 0.000 | 0.094 | 0.000 | . |